Absci Corp
ABSI Nasdaq· Services-Commercial Physical & Biological Research
Last close · Oct 23, 2026
$9.18
KIRA · Stoqly’s AI analyst, in plain words
- Absci Corp had $2.8M of revenue in fiscal 2025, down 38.2% on the year before. Over five years, revenue changed −10.1% a year on average.
- Its operating margin was −4,297.0%, down 1,895.4 pts: of every 100 in sales, about −4,297 is left after running the business.
- Absci Corp lost $115M in fiscal 2025.
- Free cash flow was −$94.0M in fiscal 2025, −3,358.3% of revenue.
Market cap
$1.4B
P/E
—
Revenue
$2.8M
Net income
−$115M
Free cash flow
−$94.0M
Operating margin
−4,297.0%
Absci Corp in 30 seconds · fiscal 2025
Are sales growing?
−38.2%
No. Sales fell 38.2% last year.
Does it make a profit?
−4,113.7%
No. It lost money last year.
Does profit turn into cash?
−3,358.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Absci Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- Absci Corp
- CIK
- 0001672688
Absci Corp · ABSI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.8M | $5.7M | $5.7M | $4.5M | $2.8M |
| Revenue growth | 0.0% | 20.2% | −0.5% | −20.7% | −38.2% |
| Operating margin | −1,573.4% | −1,857.5% | −2,020.2% | −2,401.6% | −4,297.0% |
| Net income | −$101M | −$105M | −$111M | −$103M | −$115M |
| Net margin | −2,111.3% | −1,825.4% | −1,933.6% | −2,274.1% | −4,113.7% |
| Diluted EPS | −$2.08 | −$1.15 | −$1.20 | −$0.94 | −$0.84 |
| Cash | |||||
| Cash from operations | −$60.6M | −$81.3M | −$64.6M | −$72.4M | −$92.9M |
| Capital expenditure | $38.0M | $16.2M | $0.9M | $0.4M | $1.1M |
| Free cash flow | −$98.6M | −$97.5M | −$65.5M | −$72.8M | −$94.0M |
| FCF margin | −2,062.8% | −1,696.8% | −1,145.4% | −1,605.8% | −3,358.3% |
| Share count change | 220.7% | 82.8% | 1.3% | 19.8% | 24.1% |
| Debt and strength | |||||
| Cash and short-term investments | $253M | $60.0M | $72.4M | $112M | $144M |
| Debt incl. finance leases | $9.5M | $14.0M | $8.6M | $4.1M | — |
| Shareholders' equity | $366M | $274M | $176M | $179M | $189M |
| Current ratio | 8.1x | 6.2x | 4.1x | 4.7x | 6.6x |
| Interest coverage | −21.9x | −109.8x | −114.4x | −192.7x | −575.7x |
| Returns and quality | |||||
| Return on capital | −50.8% | −37.4% | −81.7% | −121.7% | — |
| Return on equity | −73.0% | −32.8% | −49.1% | −58.0% | −62.5% |
| Return on tangible equity | −35.6% | −52.1% | −86.4% | −76.8% | −77.9% |
| Piotroski F-score | 2 | 2 | 2 | 4 | 2 |
| Altman Z'' | 7.4 | 4.1 | −2.4 | −2.5 | −1.9 |
Insiders bought, 12 months
$0.9M
4 insiders
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Absci Corp · ABSI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.18 a share, the company is worth $1.4B.
Source: SEC EDGAR XBRL filings (CIK 0001672688). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.